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ABSTRACT: The distinction between surface and bulk crystal-
lization of amorphous pharmaceuticals, as well as the importance of
surface crystallization for pharmaceutical performance, is becoming
increasingly evident. An emerging strategy in stabilizing the
amorphous drug form is to utilize thin coatings at the surface.
While the physical stability of systems coated with pharmaceutical
polymers has recently been studied, the effect on dissolution
performance as a function of storage time, as a further necessary step
toward the success of these formulations, has not been previously
studied. Furthermore, the effect of coating thickness has not been
elucidated. This study investigated the effect of these polymer-
coating parameters on the interplay between amorphous surface
crystallization and drug dissolution for the first time. The study
utilized simple tablet-like coated dosage forms, comprising a continuous amorphous drug core and thin polymer coating (hundreds
of nanometers to a micrometer thick). Monitoring included analysis of both the solid-state of the model drug (with SEM, XRD, and
ATR FTIR spectroscopy) and dissolution performance (and associated morphology and solid-state changes) after different storage
times. Stabilization of the amorphous form (dependent on the coating thickness) and maintenance of early-stage intrinsic dissolution
rates characteristic for the unaged amorphous drug were achieved. However, dissolution in the latter stages was likely inhibited by
the presence of a polymer at the surface. Overall, this study introduced a versatile coated system for studying the dissolution of thin-
coated amorphous dosage forms suitable for different drugs and coating agents. It demonstrated the importance of multiple factors
that need to be taken into consideration when aiming to achieve both physical stability and improved release during the shelf life of
amorphous formulations.
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1. INTRODUCTION
Surface crystallization of amorphous drugs is distinct and
orders of magnitude faster than bulk (interior) crystalliza-
tion.1−6 This is believed to be due to the higher molecular
mobility of surface molecules, with multiple observations in the
pharmaceutical setting consistent with this theory. For
instance, the crystallization of amorphous drug particles
depends on their specific surface area, with smaller particles
(which may otherwise be desired for improved solubility and
dissolution rate), crystallizing faster and more extensively.1,7
Further, gratings on amorphous drug surfaces flatten and
disappear over time, which has been attributed to the surface
molecular diffusivity being a million-fold higher than that of
the bulk.8,9 Depletion zones visualized around surface crystals
are yet another example illustrating highly mobile amorphous
molecular surfaces.4,10
The most established approach for stabilizing amorphous
drugs is to form amorphous solid dispersions with polymers.
While the formation of solid dispersion can stabilize the bulk,
surface crystallization may still occur.11 An approach
orthogonal to amorphous solid dispersions is to stabilize the
more sensitive surfaces of amorphous materials, with or
without additionally stabilizing the bulk of the material. This
strategy benefits from a lowered polymer (or other excipient
used for stabilization) burden and ideally should be simple and
scalable. Whether or not this approach requires specific types
of interactions between the drug and the stabilizing agent or
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whether the principle of physical coverage on its own is
enough to lower the molecular mobility at the surface to that
of the bulk is still uncertain.
In 2006, Wu and Yu demonstrated that simple amorphous
drug film surface coverage with a microscope slide (silicate
coverslip) inhibited crystallization, and this can broadly be
considered the initial pharmaceutical research into surface
crystallization.1 Subsequently, gold and strong polymer
polyelectrolytes were among the first materials shown to
inhibit the surface crystallization of amorphous drugs in
coating layers as thin as 10 and 3−20 nm, respectively.3,12
Surface stabilization by the pharmaceutically more relevant
dextran, alginate, and chitosan followed, among other studies.
While the gold film was sputtered or vacuum deposited,3 the
strong polymer polyelectrolyte12 and dextran,5 alginate,6 and
chitosan13 films were selected and deposited based on the
coating material having a charge opposite to that of the drug
molecule, resulting in ionic interactions between the drug and
the coating. Thin polymer coatings have also been used to
stabilize solid dispersions, with the same polymer used as both
the matrix and coating agent.14 Dry coating of solid dispersions
with carnauba wax also resulted in a very stable product, where
the matrix was stabilized with a different polymer.15 More
recently, 20 nm thick gelatin efficiently inhibited surface
crystallization with no strict requirement of opposite charges
between the drug and the stabilizing agent.16
While these studies highlight the potential of diverse
coatings to inhibit surface crystallization, surface coating
studies involving polymers used as pharmaceutical excipients
are limited.5,6,13,16,17 The majority of these surface coating
studies have focused on the improvement of storage stability of
amorphous systems. Additionally, some of the study designs
are not likely to be implemented on a larger scale due to
pharmaceutically irrelevant materials or difficult-to-scale
processes, involving multiple steps (preparation of amorphous
material, preparation, and consequent coating and rinsing/
drying of particles, from which the final dosage form must be
made). Furthermore, the dissolution performance as ultimately
the most important critical quality attribute of such systems
remains less studied,5,6,13 particularly, in stability monitoring.12
Studies thus far have focused on the dissolution of individually
coated amorphous particles5,6,13 or such particles compressed
into a tablet.12 As the ultimate goal of amorphous drug
formulations is to improve solubility and oral bioavailability,
the stabilized amorphous drug systems must perform well in
dissolution testing during the full shelf life, in addition to
having adequate physical stability.
This study investigates the surface stabilization of a simple
dosage form consisting of an amorphous drug compact that
was subsequently spray-coated with a thin polymer layer. As
only the final amorphous dosage form (compact) is coated
instead of individual drug particles, the total amount of
polymer used is minimized. We wanted to see if such a simple
system with this minimal amount of a coating agent can
provide maintenance of the intrinsic dissolution rate during
dissolution in a pharmaceutically relevant setting. In addition,
the effect of coating thickness (a varying amount of polymer
coating) on the interplay between stabilization during storage
and dissolution was investigated.
2. MATERIALS AND METHODS
2.1. Sample Preparation. 2.1.1. Preparation of Different
Solid-State Forms of Indomethacin. Amorphous indometha-
cin was prepared by melting the γ form (Hovione Farm-
aCiencia SA, Loures, Portugal) at 170 °C, followed by cooling
to 5 °C. The α form of indomethacin was prepared by adding
Milli-Q water to an ethanol solution of indomethacin at 80 °C.
Precipitated crystals were vacuum filtered and dried overnight.
The ε form of indomethacin was prepared from the slurry of an
amorphous form in pH 6.8 buffer.18,19 The solid-state forms
were confirmed with X-ray diffractometry (XRD), attenuated
total reflectance Fourier transform infrared spectroscopy (ATR
FTIR), and differential scanning calorimetry (DSC).
2.1.2. Preparation of Compacts with Vacuum Compres-
sion Molding. Amorphous indomethacin was loaded into a
polytetrafluoroethylene (PTFE) Teflon foil lining within the
MeltPrep cylindrical chamber (MeltPrep GmbH, Graz,
Austria). Compacts were formed by vacuum compression
molding (VCM)20,21 at 70 °C (above the Tg of indomethacin)
for 10 min, followed by cooling for 10 min on a steel unit. This
corresponds to an approximate cooling rate of 5 °C per
minute. The piston (20 mm in diameter) created a compaction
pressure of 2.6 bar. The resulting compacts were transparent,
yellow, and brittle, much like the solidified melt upon quench
cooling. The compacts weighed 500 ± 10 mg and had a height
of approximately 1.3 mm and a diameter of 20 mm. Their
amorphous nature was confirmed with polarized light
microscopy (PLM) through an absence of any visible
birefringence, and XRD, by the presence of an amorphous
halo. These compacts are referred to as uncoated (N)
throughout the study.
2.1.3. Preparation of Compacts with Hydraulic Compres-
sion. Compacts composed of α indomethacin were prepared
by manual hydraulic compression (Manual Hydraulic Press,
Specac Ltd., Orpington, U.K.) for 30 s with 1 ton and were
further used as a reference for intrinsic dissolution testing.
2.1.4. Ultrasonic Spray Coating of Compacts. Some of the
freshly prepared amorphous indomethacin compacts were
spray-coated with polyvinylpyrrolidone (PVP K30, average
molecular weight (Mw) 40 000, Sigma-Aldrich, St. Louis,
Missouri, USA) using an Exacta Coat Ultrasonic Spraying
system (Sonotec, Milton, New York, USA). Prior to coating,
the samples were kept in a desiccator with silica pearls. The
coating solution was 0.5% w/v PVP K30 in Milli-Q water.22
Compacts were placed on a temperature-controlled sample
stage and sprayed with a polymer solution from the ultrasonic
spraying nozzle placed above the compact. One of the compact
faces was coated by programing the path of the nozzle in the x
and y directions, while keeping the distance of the nozzle from
the samples (z) the same.22 The number of coating cycles (full
paths of the nozzle above the sample) applied was either two
(2C) or ten (10C), resulting in coatings hundreds of
nanometers or approximately a micrometer in thickness,
respectively. The coating solution was applied at an infusion
rate of 0.1 mL/min. Taking into account the coating and dwell
times, as well as the starting concentration of PVP solution, it
can be estimated that 10 cycles of coating corresponded to a
deposition of a maximum of 4.45 mg of PVP per compact,
which weighed 500 mg (roughly 1% w/w). To ensure
complete coalescence of the sprayed droplets, the sample
stage below the nozzle was heated to 30 °C (below the Tg of
indomethacin), with a dwell time of 30 s in between each
coating cycle. PVP was selected as a stabilizing agent due to its
documented ability to stabilize amorphous indomethacin.23,24
2.1.5. Storage. The stability of the compacts was monitored
during storage at 30 °C and 75% relative humidity (RH),
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.9b01263
Mol. Pharmaceutics 2020, 17, 1248−1260
1249
obtained with a saturated solution of sodium chloride. Day 0
uncoated samples were analyzed within 24 h of preparation. All
coated samples had their polymer-coated side exposed to the
humid environment.
2.2. Analytical Methods. 2.2.1. Scanning Electron
Microscopy (SEM). For imaging the compact faces, compact
sections were placed on stubs covered with double-sided
carbon tape. To image compact cross sections, compacts were
broken to create new surfaces perpendicular to the top surface
just before platinum sputter coating. The micrographs were
collected with an FEI Quanta 250 field emission gun SEM
(FEI, Hillsboro, USA) microscope using a high vacuum, a
voltage of 3−5 kV, and an Everhart Thornley Detector (ETD).
2.2.2. X-ray Diffractometry (XRD). Diffractograms were
obtained using a Malvern Panalytical Empyrian (PANalytical
B.V. Almelo, The Netherlands) instrument in reflection mode
with Cu Kα1 radiation (λ = 1.5406), divergence slit of 0.19
mm, generator voltage of 45 kV, and a tube current of 40 mA.
Diffractograms were collected from 5 to 50° 2θ with a step size
of 0.013°. The compacts were rotated during the measure-
ments.
2.2.3. Attenuated Total Reflectance Fourier Transform
Infrared Spectroscopy (ATR FTIR). A minimum of triplicate
infrared spectra of the compact faces was obtained using a
Vertex 70 spectrometer (Bruker Optics, Ettlingen, Germany)
equipped with a MIRacle ATR single-reflection crystal (Pike
Technologies, Wisconsin, USA) and a DLaTGS detector. The
spectra (averages of 256 scans with a spectral resolution of 4
cm−1) were collected using OPUS 8.1 (Bruker Optics,
Ettlingen, Germany) software.
2.3. Intrinsic Dissolution Testing. Dissolution tests were
performed using the Erweka DT6 paddle apparatus (Erweka
GmbH Langen, Germany) operated at 50 rpm. Prior to the
dissolution experiments, the radial band and one round flat
surface of each of the compacts were coated with transparent
nail polish containing nitrocellulose and tosylamide/epoxy
resin (shellac) as waterproof agents (Mavala Switzerland base
coat).12 In this way, only one surface of the compacts was
exposed to the dissolution medium, allowing intrinsic
dissolution testing analysis. Where applicable, the exposed
surface was that previously coated with the PVP. Compacts
(obtained by vacuum compression molding) had an exposed
face surface area of 3.14 cm2, while the reference tablets
composed of α indomethacin (prepared by hydraulic single
punch press) had a corresponding area of 1.33 cm2. The
dissolution medium was 900 mL of phosphate buffer with a pH
of 6.8 at 37 °C. Dissolution medium samples were withdrawn
at selected time points and replaced with the same volume of
preheated buffer. The dissolved drug concentration (unfiltered
samples) was measured with UV spectrophotometry (UV-
1600PC UV−Vis spectrophotometer, VWR, China) at 318
nm. All dissolution experiments were performed in triplicate.
The compacts remained as one piece after 45 min of
dissolution testing, which allowed for their collection from
the dissolution vessel and subsequent solid-state analysis.
3. RESULTS
3.1. Coating Thickness and Uniformity. Coating
thickness and uniformity, as well as the adherence to the
compacts, were assessed based on SEM images of compact
surfaces and cross sections. As can be seen from cross-sectional
SEM images in Figure 1, the core of the tablet and coating
layers exhibited different appearances and allowed for
estimation of the coating thickness: 10 coating cycles produced
final coatings roughly 1 μm thick, whereas 2 coating cycles
formed a layer approximately 200 nm thick. The coating
appeared uniform and well adhered to the surface of the drug
compacts throughout the storage study. For instance, the
surface of samples coated with 10 cycles on day 7 revealed a
smooth coating that was still intact, while the cross-sectional
images suggested complete adherence.
3.2. Effect of Coatings on Physical Stability during
Storage. 3.2.1. Morphological Analysis. The stability of the
uncoated (N) samples was compared to the two types of PVP-
coated samples (coated with two (2C) or ten (10C) spraying
cycles) by monitoring for up to 28 days of storage at 30 °C/
Figure 1. SEM micrographs of the top surface and cross sections of amorphous indomethacin compacts stored at 30 °C/75% RH; (a) uncoated
(N), (b) PVP-coated with two spraying cycles (2C), and (c) PVP-coated with ten spraying cycles (10C). The black areas on the top right of some
cross-sectional images represent a vacuum. This is also indicated by arrows in the figure.
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75% RH. As both coated and uncoated samples were prepared
in the same manner with VCM, any potential nucleation sites
(undetected with PLM and XRD) would have been similarly
present in all studied samples, which allowed for direct
comparison of their crystallization tendency. First, we wanted
to see whether the crystallization was surface biased
qualitatively. Crystallization progression was estimated based
on the SEM micrographs of the compact surfaces and cross
sections. Surface and cross sections of the day 0 sample
exhibited a smooth appearance (Figure S1). Figure 1 provides
an overview of differences among the samples stored for 7, 14,
and 28 days. In all samples, the crystallization was limited to a
thin layer at the compact drug surface, no deeper than 50 μm
on the 1.3 mm thick compacts, despite the moisture acting as a
plasticizer, which, if absorbed beyond the surface into the core,
would theoretically promote crystallization in the core as
well.25 This is easily seen, especially in the cross-sectional SEM
images, as both the amorphous drug and polymer appear
smooth, in contrast to the roughly textured crystalline areas.
All observed crystals were needle-shaped.
The crystallization during storage included growth both out
of and into the interior of the compacts. The cross-sectional
images revealed that the surface crystallization first progressed
toward the interior of compacts, with crystals sporadically
emerging above the surface after 7 days, mostly on the
uncoated samples. The surface view of the same samples
revealed that, at that time point, the crystals were largely
aligned with the surface, while at 14 or 28 days, the crystals
grew in number and protruded up to 5−10 μm above the
compact surface. With both the 2C- and 10C-coated samples,
the needle crystals appeared to grow from underneath the
coating and then emerge above the coated surface. For
instance, images of the 2C samples at day 7 reveal that some of
the needles penetrated through the coating, while others were
still covered by the polymer.
SEM images indicate that the coating presence, as well as
thickness, influenced crystallization behavior in both the
outward and inward directions. This is particularly evident at
the end of the storage study. Almost the entire surface of the
day 28 N samples was covered with needle-shaped crystals
proceeding both outward and inward. In comparison, coated
samples had fewer areas with outward growing crystals. The
density of these areas was higher with the thinner coating; the
thicker coated surface was still mostly devoid of crystals. In
addition, the cross-sectional images show that the crystal-
lization toward the interior was slightly deeper for the thinner
coating and was similar to the uncoated samples. Depletion
zones in between amorphous and crystalline areas were also
visible, particularly in the early days of storage with the
uncoated samples. For instance, the top surface of the
uncoated sample on day 3 depicts such zones, which resemble
microcracks (Figure S2).
3.2.2. Solid-State Analysis. XRD and ATR FTIR were
employed for complementary solid-state characterization. As
the compacts were rotated during the XRD measurements and
the scans were performed in reflection, the diffractograms
depicted in Figure 2 show the average solid-state profile biased
toward the compact surfaces. Taking into account the density
of discs and the element weight fractions of indomethacin, it
can be estimated that 90% of the diffraction signal originates
from within 200 μm of the surface, whereas 50% of the
diffraction is generated from within 100 μm of the surface
(Figure S3). On the other hand, ATR FTIR measurements
shown in Figure 3 provide even more surface-specific solid-
state information, with sampling from a minimum of three
different regions at the sample surfaces. Based on refractive
indices of PVP and diamond (approximately 1.5 and 2.4,
respectively) and an angle of incidence of 45°, it can be
estimated that the depth of penetration of the evanescent wave
in this set up was between 1.34 and 1.01 μm in the spectral
Figure 2. XRD reflection patterns of (a) uncoated (N), (b) PVP-coated with two cycles (2C), and (c) PVP-coated with ten cycles (10C)
amorphous indomethacin compacts during storage at 30 °C/75%RH. In all cases, day 0 represents the neat amorphous (uncoated) indomethacin
compact within 24 h from preparation. Characteristic peaks of α indomethacin are marked in green.
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range of 1500−2000 cm−1. In addition to the more global
(XRD) versus targeted area and surface-biased (ATR FTIR)
sampling, the selected characterization techniques are
especially complementary, as ATR FTIR is highly sensitive
to the presence of PVP, which, being amorphous, can be
considered invisible to XRD in this context.
As can be seen in Figures 2 and 3, the PVP coating delays
the onset of crystallization at 30 °C/75% RH. According to the
XRD analyses (Figure 2), the first signs of crystallization were
observed at day 3 for uncoated samples, day 7 for 2C-coated
samples, and day 14 for 10C-coated samples. The onset of
crystallization estimated with the XRD matches the ATR FTIR
results (Figure 3), with the exception of the 10C-coated
samples, whose PVP coating layer dominated the ATR signal.
As mentioned above, the depth probed with ATR FTIR in the
wavenumber region of interest in the current study is estimated
to be just above 1 μm, which explains why the PVP signal (of
∼1 μm thick layer) dominated the spectra of 10C-coated
samples.
Another interesting observation from the ATR FTIR spectra
(Figure 3c) is a trend of the PVP carbonyl stretch peak to shift
toward lower wavenumbers during storage, which is likely due
to polymer−water interactions.
As expected from previous studies,26,27 crystallization of the
amorphous indomethacin at 75% relative humidity was
predominantly to the α form. Exceptionally, one ATR FTIR
spectrum of the uncoated sample on day 14 was dominated by
the signal from the γ form. With a sampling area of 2.5 mm2,
this demonstrates some degree of heterogeneity in the
resulting polymorphs, as has been observed previously.27
Overall, these results indicate that crystallization inhibition
depends on the coating thickness, a thicker coating provided
protection for a longer period of time.
3.3. Effect of Coatings on Dissolution Performance.
3.3.1. Dissolution Behavior. The intrinsic dissolution behavior
of uncoated versus polymer-coated samples with two different
coating thicknesses was tested for 45 min in pH 6.8 phosphate
buffer. The reported solubility of indomethacin at this pH is
835 μg/mL,28 which greatly exceeds the highest measured
concentrations, confirming that the sink conditions were
maintained in this study. Cumulative dissolved amounts of
drug versus time profiles are depicted in Figure 4. Intrinsic
dissolution rates (IDR) were calculated by linear regression
from the early time points. Improvement in IDR of the
amorphous versus α form of indomethacin was approximately
2-fold in the first 10 min of the tests.
During the initial stages of dissolution, lasting for
approximately 5 min, we can assume that no significant
solution-mediated crystallization is taking place, as the profiles
appear linear. During this initial phase of dissolution, there was
a trend toward a decreased dissolution rate upon increased
storage time for the uncoated samples, with day 28 samples
having the lowest IDR (Figure 4a). During this same time
period, the dissolution profiles for both 2C- and 10C-coated
samples closely follow that of the fresh uncoated amorphous
samples (day 0), even upon being subjected to a short storage
time at high humidity (Figure 4b,c). In contrast, the coated
samples stored for longer periods of time trended toward a
decreased IDR when compared to the fresh uncoated
amorphous samples. This can be best seen from Figure 4b,
where the dissolution profiles of the day 3 and day 7 samples
closely resemble that of the fresh uncoated amorphous
samples, whereas the day 14 and day 28 samples are rather
similar to the profile of α indomethacin. Similarly, the IDR of
the 10C-coated samples stored for 14 days was also equal to
that of the uncoated amorphous indomethacin, however, for a
shorter duration of dissolution, when compared to the 2C
Figure 3. ATR FTIR spectra of (a) uncoated (N), (b) PVP-coated
with two cycles (2C), and (c) PVP-coated with ten cycles (10C)
amorphous indomethacin compacts during storage at 30 °C/75%RH;
am = amorphous.
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samples. This correlates well with the overall preserved
amorphous nature of coated samples stored short-term prior
to dissolution (Figures 2 and 3); up to day 7 for the thinner
coatings and up to day 14 for the thicker coatings.
In the second phase of dissolution, during which curvature
in the dissolution profiles (which typically indicates a solution-
induced crystallization) was observed, there is a clear
difference between the uncoated and 2C-coated samples on
the one hand and the 10C-coated samples on the other hand.
This is evident when the profiles are compared to that of the
uncoated α indomethacin tablets (color-coded in green in
Figure 4). Whereas the uncoated and 2C-coated samples are
distributed around the α indomethacin profile, all 10C-coated
samples have profiles whose concentrations were below those
of the α indomethacin. Thus, the dissolution behavior was
dependent on the original coating thickness.
3.3.2. Surface Morphology upon Dissolution. A compar-
ison of surfaces and cross sections of compacts after 45 min of
dissolution testing is depicted in Figure 5. In general, the
surface of uncoated samples was much rougher after the
dissolution testing. On the other hand, the surface of the
coated samples, especially with 10C, was still smooth in many
areas even after dissolution testing. For instance, after 28 days
of storage, both the 2C- and 10C-coated samples contained
smooth amorphous looking regions among the crystallized
zones.
In complete contrast to before dissolution, all SEM cross-
sectional images of samples after dissolution show the
disappearance of needle-like crystals protruding above the
surface of the compacts. Needles were still present on (and
limited to) the surface; however, they were oriented parallel
rather than perpendicular to the surface.
Some of the largest needle crystals that were embedded
comparatively deep within the compacts were not dissolved or
washed away. For example, 2C cross-sectional image on day 28
(also included as a larger image in Figure S4) reveals several
outward protruding crystals after the dissolution, with
additional smaller crystals that presumably grew during
dissolution testing, appearing around and on top of the larger
crystals. This order of crystallization is highly likely considering
that the storage-induced crystallization yielded outward
growing crystals, whereas the solution-mediated crystallization
yielded crystals in line with the surface.
Another profound difference is the presence of additional
surface morphology not observed prior to dissolution testing.
Spherulite structures were visible on the surface of multiple
samples in Figure 5. Cross-sectional images of these same
regions reveal compact surfaces indentations, tens of micro-
meters, even up to 100 μm deep, which were covered
exclusively by the spherulite-like structures.
3.3.3. Solid-State Transformations Occurring during
Dissolution. The heterogeneity of the sample surfaces upon
45 min of dissolution testing is visibly evident from Figure 6.
Already at the macroscopic level, distinctive regions charac-
terized by color and texture can be identified. The character-
ization techniques allowed the targeted characterization of
these different regions, as well as the overall solid-state and
chemical analysis at the surfaces of the samples. The
combination of ATR FTIR (with a sampling diameter of
approximately 2 mm) and XRD (with the whole sample under
rotation) was especially suitable for this purpose.
Both XRD (Figure 7) and ATR FTIR (Figure 8) results
indicate that crystallization also occurred during dissolution.
For instance, diffractograms of the uncoated day 0 and day 3
samples after dissolution testing show crystalline peaks above
the amorphous halo that were not present prior to dissolution.
Crystals formed during storage also dissolved during the
Figure 4. Intrinsic dissolution profiles of (a) uncoated (N), (b) PVP-
coated with two cycles (2C), and (c) PVP-coated with ten cycles
(10C) amorphous indomethacin compacts during storage at 30 °C/
75%RH. Profiles represent mean values plus one standard deviation of
three measurements. The α indomethacin is uncoated in all graphs.
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dissolution study, leading to an apparent decrease in
crystallinity. This is evident from Figure 7b, for example,
with 2C day 14 and day 28 samples, which were more
amorphous after than prior to dissolution.
ATR FTIR spectra provide evidence that the PVP dissolved
during dissolution. This conclusion is made based on the
complete absence of the PVP signal after dissolution (Figure
8).
Multiple solid-state forms were identified after 45 min of
dissolution testing. Crystallization during dissolution, as well as
storage, was predominantly to the α form of indomethacin.
However, some peaks in the XRD diffractograms also indicate
the formation of the ε form, though to a lesser extent than the
α form. The presence of the ε form is more evident from the
ATR FTIR measurements, in which this polymorph was
detected in a significantly larger number of samples, due to the
targeted analysis. The formation of the ε form was only
observed upon, and never prior to, dissolution.
4. DISCUSSION
4.1. (Pre)Formulation Aspects. The use of vacuum
compression (MeltPrep) enabled the preparation of air-
bubble-free compacts (tablet cores) without any mechanical
grinding. This preparation method preserves the amorphous
nature of indomethacin glass and avoids any potential
crystallization induced by grinding and compaction, which
Figure 5. SEM micrographs of the top surface and cross sections of amorphous indomethacin compacts stored at 30 °C/75%RH that underwent
intrinsic dissolution testing for 45 min; (a) uncoated (N), (b) PVP-coated with two spraying cycles (2C), and (c) PVP-coated with ten spraying
cycles (10C). The black areas on the top right of some cross-sectional images represent a vacuum. This is also indicated by arrows in the figure.
Figure 6. Photographs of compacts after 45 min of dissolution testing: (a) uncoated (N), (b) PVP-coated with two spraying cycles (2C), and (c)
PVP-coated with ten spraying cycles (10C). Marker pen writings (in red and black) at the bottom of compacts are visible due to the transparency
of the samples.
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may be present in the case of compressed amorphous powders.
Further, vacuum compression minimizes the existence of any
voids and free surfaces typically present upon mechanical
compression, which would otherwise enable surface-facilitated
crystallization within the compacts. One flat face of such tablet
cores was then spray-coated with PVP. The approach used in
this study was to simplify the “formulation” in order to single-
out the impact of a single excipient, in this case, PVP, on
storage and dissolution behavior, and thus to exclude the
complicating effect of further components on data interpreta-
tion, such as any potential film plasticizer. In the design of the
storage study, the moisture acted as a coating plasticizer. No
drying, peeling, or cracking of the film coating was observed in
the time frame of the study by visual inspection. The aqueous
coating solution employed was considered more suitable to
preserve amorphousness than an organic-based solution, as the
latter is more likely to dissolve the drug and thereby induce
crystallization partially.29 The poor aqueous solubility of the
drug (indomethacin) thus actually works in favor of aqueous-
based coating systems. No change in color or opacity,
indicating crystallization after applying the coatings, was
observed upon visual inspection. Unlike with compressed
amorphous powders, visual inspection of MeltPrep compacts
was possible due to the transparency, characteristic for
amorphous glasses, being preserved.
It is important to note that the studied coatings, being
hundreds of nanometers to a micrometer thick, were much
thinner than the tablet-like compacts, at more than a
millimeter in thickness. Hence, the polymer coatings are
considered to be thin in this context. In comparison, previous
studies on storage stability performance of surface coatings
have typically employed coatings that are several nm (up to
10−20 nm) thick, on amorphous films that were tens of μm
thick.16 The dissolution performance was assessed with coated
amorphous particles, typically 45−100 μm in size.5,6,13 Overall,
the employed sample preparation techniques, vacuum
compression molding, and spray coating offered high precision
and control and are likely to be suitable for the other drug−
polymer systems as well.
It is also important to highlight that our dissolution study
involved testing of a whole polymer-coated dosage form (with
one polymer-coated surface exposed to medium) rather than
individually coated particles dispersed in a dissolution vessel,
which limits the interpretation of the results in the present
study in relation to these previous studies. Single compact and
individual particle motions in the dissolution medium differ
significantly. Further, the total amount of polymer is much
lower for coated compacts then for coated drug particles.
4.2. Properties of PVP (Films) That Govern Surface
Stability during Storage. There are multiple properties of
PVP that govern its effect on the amorphous drug behavior
during storage and dissolution. In general, the following
properties of polymers affect the stabilization efficacy during
storage: (i) Tg and the antiplasticizing effect, (ii) presence of
specific drug−polymer interactions, (iii) drug−polymer
miscibility, (iv) hygroscopicity, and (v) viscosity (related to
Mw) of the polymer.
17
The stabilizing role of PVP during storage is supported by its
ability to interact with the drug specifically. Molecularly
dispersed PVP in concentrations as low as 1% have been found
to reduce amorphous indomethacin crystallization rates during
storage at 30 °C (the humidity was not reported).7 The
mechanism of stabilization is not only the antiplasticizing effect
(raising the Tg of the drug).
30 Specific hydrogen bonding
between the hydroxyl group of indomethacin and carbonyl
group of PVP was found to be the main factor preventing the
hydrogen bonding within indomethacin dimers, which would
lead to crystallization.24 Another polymer, Eudragit E PO,
which is capable of forming ionic bonds with indomethacin,31
was found to be an even more efficient inhibitor of
Figure 7. XRD reflection patterns of compacts before and after 45 min of dissolution testing: (a) uncoated (N), (b) PVP-coated with two spraying
cycles (2C), and (c) PVP-coated with ten spraying cycles (10C). Characteristic peaks of α and ε forms of indomethacin are marked in green and
blue, respectively.
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crystallization, further indicating the importance of molecular
interactions.32 Similar findings have been reported for other
drugs as well.33 Recent reports on effective nanocoating
materials have all relied on ionic interactions.5,6,13 On the other
hand, hydrogen bonding or other molecular interactions on
their own are an insufficient predictor of stabilization, as the
vinylpyrolidone (VP) dimer had little effect as a crystallization
inhibitor, in contrast to polymeric PVP.11 Indeed, even though
the extent of hydrogen bonding across different grades of PVP
and indomethacin did not differ,34 grades with higher
molecular weight and viscosity were found to be more efficient
stabilizers compared to the lower molecular weight and
viscosity grades.34−36 In theory, drug−polymer interactions
in the current study would be visible in ATR FTIR spectra of
2C samples (Figure 3b), in which both drug and the polymer
peaks were observed. However, these two components had
varying signal intensities, which hindered the ability for
interaction detection. Although we did not detect hydrogen
bonding with ATR FTIR in this study (mainly due to the
interactions being limited to the drug−polymer interface, and
the sampling volume of ATR FTIR being much larger), such
interactions at the very thin drug−polymer interfacial layer are
probable, since they have been reported for indomethacin-PVP
solid dispersions. In addition, hydrogen bonding of indome-
thacin or PVP with water molecules could have masked any
detectable carbonyl peak shifts arising from drug−polymer
interactions. The observed shift of PVP carbonyl peak at
around 1650 cm−1 toward lower wavenumbers in the 10C-
coated samples (Figure 3c) indicates PVP−water interactions.
Wan et al.37 reported this red shift in ATR FTIR spectra of
PVP K90 films exposed to 70% RH at 25 °C.
Another related and important factor in relation to storage
solid-state stability, particularly upon exposure to high
humidity conditions, is polymer hygroscopicity.17 Our ATR
FTIR spectra of 10C coatings show a PVP carbonyl peak shift
to lower wavenumbers during storage, which is evidence for
PVP−water interactions. In this respect, PVP is highly
hygroscopic, as it absorbs approximately 40% moisture upon
exposure to 80% RH,38 or 38% at the humidity used in this
study (75% RH).17 Some studies suggest that hygroscopic
polymers such as PVP may prefer to hydrogen bond with water
instead of the drug,17,39 which could make them less effective
stabilizers compared to nonhygroscopic polymers (such as
Soluplus or Eudragit E PO, for example).17 Out of the latter
two, the less hygroscopic similar grade of Eudragit E was found
more effective at amorphous form stabilization during storage
than Soluplus, which supports this view.40 In the current study,
despite their hygroscopicity, PVP coatings stabilized the
amorphous drug during storage, and their effect depended
on the coating thickness. This could potentially be caused by
the greater barrier provided by a thicker coating, making the
outward growth of needles more challenging.
During storage, we observed axial (outward) crystal growth
at the surface of pure amorphous indomethacin compacts and
compacts spray-coated with PVP. Lateral crystal growth
(sideways, with respect to the sample surface in between two
microscope coverslips) of amorphous nifedipine11 and
indomethacin41 has been reported earlier. The authors argued
that the most likely mechanism for this phenomenon is the
surface transport of molecules originating from the glass
surface. In support of this explanation, we and the others4,10
have observed depletion zones, which look like microcracks in
between amorphous and crystalline areas at the surface, as
shown in Figure S2.
The crystallization during storage mainly yielded the α form
of indomethacin. This is in agreement with previous studies of
amorphous indomethacin crystallization at high humidity.26,27
Figure 8. ATR FTIR spectra of compacts after 45 min of dissolution
testing: (a) uncoated (N), (b) PVP-coated with two spraying cycles
(2C), and (c) PVP-coated with ten spraying cycles (10C). Where
applicable, different targeted areas at the surface of compacts (spot
(s), yellow (y), and diffuse white regions (w)) are indicated in the
legend; am = amorphous.
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4.3. Dissolution Performance. According to the Noyes−
Whitney equation, factors influencing dissolution rate include
(i) the solubility of the solid at the dissolving surface, which is
dependent on the solid-state form of the solid (amorphous
versus existing or different crystalline forms forming during
dissolution) and presence of any solubility enhancers such as
polymers, (ii) dissolving surface area, which can be affected by
potential crystallization occurring during dissolution, as well as
on the morphology and surface coverage with newly formed
crystals, and (iii) thickness of the diffusion layer, which is
affected by the viscosity at the surface.
In addition to the factors governing the effect of PVP on
stability during storage, during dissolution, the presence of a
(pre)dissolved polymer can inhibit crystallization based on the
following mechanisms: (i) cosolvent effect of the polymer that
reduces the supersaturation and, thus, the driving force for
recrystallization, (ii) coverage of growing crystal faces with the
polymer, and (iii) presence of polymer film at the surface,
which hinders nucleation.42
Even though beneficial to the stability of the amorphous
forms, the higher viscosity afforded by the polymer might
adversely affect dissolution. It is expected that the presence of
PVP in the dissolution medium provides a parachute effect for
maintaining the supersaturation of indomethacin.43 The
incorporation method can also have an effect, and solid
dispersions were shown to be better at maintaining super-
saturation than the predissolved polymer42 or drug and
polymer physical mixtures. In the current study, PVP-coated
samples stored at high humidity did not outperform the IDR of
fresh amorphous indomethacin; however, the physical
stabilization during storage and maintenance of early-stage
IDR were achieved. The increase in viscosity caused by the
PVP, which has an average molecular weight of 40 000, is
probably one of the reasons for the observed dissolution
behavior. The impaired performance in the latter stages of
dissolution was especially evident for the 10C-coated samples.
Such an effect has previously been reported with indomethacin
spray-dried with PVP: a decreased IDR with increased PVP
content was attributed to increasing the viscosity of the
particle-localized PVP.44 Small increases in medium viscosity,
representing those of water (0.7 mPa s), milk (1.4 mPa s), or a
nutrient drink (12.3 mPa s), have also been shown to
significantly lower the dissolution rate.45 In our case, the
overall amount of PVP dissolved in the medium is small and
estimated to be approximately 0.005 mg/mL for 10C-coated
samples.
During the initial (early-stage) dissolution period, we can
assume that no solution-mediated crystallization is taking place
(no change in the surface area nor recrystallization-induced
change in solubility), and the polymer is not fully dissolved yet
(viscosity effects may be present). In this stage, there were no
differences in the IDR of freshly prepared uncoated amorphous
indomethacin and short-term stored coated samples (2C and
10C), in contrast to all stored uncoated (N) samples and long-
term stored coated samples (2C and 10C), that had decreased
IDRs. This would indicate that the dissolution performance in
this stage is mainly dependent on the storage time, or in other
words, the level of crystallinity present prior to dissolution. As
the crystallinity is increasing during storage, the solubility at
the surface is decreasing (as well as the dissolution rate). As an
opposing factor, the storage-induced formation of α
indomethacin needles protruding above the surface increases
the surface area (and dissolution rate), although this effect is
more significant for the uncoated samples, in which the needles
formed sooner and to a greater extent. The observed behavior
indicates that the polymer coatings are not having a significant
effect on this early stage of dissolution, with the effects of
increased viscosity at the surface (decreasing the dissolution
rate) on the one hand, and increased solubility of the drug
(and the dissolution rate) on the other hand, canceling each
other out.
During the later stages of dissolution, once presumably
solution-mediated recrystallization has already started (as
indicated by the curvature in dissolution profiles), the factors
influencing the rate of dissolution are changed. Most
importantly, the recrystallization from the solution causes a
decrease in solubility (and dissolution rate) and an increase in
the dissolving surface area (and dissolution rate). Further, at
this stage, the polymer has already largely dissolved but is likely
to be still affecting the surface crystallization. Based on the
appearance of samples collected after dissolution, the presence
of polymer has a surface-smoothing effect by virtue of
crystallization inhibition, which overall decreases the dis-
solution rate, by lowering the surface area despite maintaining
the amorphous solubility (in comparison to uncoated
samples). Further, the increased viscosity and/or higher PVP
concentration available for interaction at this stage may hinder
the release. Higher concentrations of PVP can cover the
dissolving surface to a greater extent, which hinders nucleation
and prevents the growth of existing crystal faces. Together,
these factors can explain why the thicker PVP coating inhibits
the dissolution more strongly in this stage, and the perform-
ance of samples introducing larger amounts of PVP is worse
than that of the α indomethacin and thinner coated samples.
In addition to variability caused by the dynamic nature of
competing dissolution and recrystallization processes, specific
test conditions such as the actual agitation speed and behavior
of submerged compacts may have contributed to the variability
in the dissolution profiles. Namely, in addition to the
dissolution-profile curvature indicating solution-mediated
solid-state transformation, sigmoidal curvature was also
observed in some of the dissolution profiles. This could, at
least partly, be due to the hydrodynamic conditions in the
vessel. Namely, as opposed to the rotating disk apparatus,
where the studied surface is fixed and exposed to the same
hydrodynamic conditions throughout the test, in the current
approach, the tablet in the vessel might end up with either the
studied (uncoated or PVP-coated) or nail polish side facing
upward in the medium. In addition, many of the compacts
were mostly static (lacking movement) at the beginning of the
tests and started substantially more movement after approx-
imately 10 min.
In addition to the formation of the α polymorph, which was
also detected during storage, crystallization to the ε form also
occurred during dissolution in phosphate buffer at pH 6.8.
This is consistent with our previous studies18,46 and an
unnamed polymorph of indomethacin reported by others.47,48
The increase in surface area during dissolution occurred
mainly due to the formation of ε form-rich spherulite-like
structures that formed indentations tens of micrometers deep
into the surface. The porosity of these spherulite structures
likely facilitated further dissolution and solution-mediated
crystallization (relative to their size and number on each of the
tested samples), in addition to the increase in the surface area
caused by the formation of α indomethacin needles.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.9b01263
Mol. Pharmaceutics 2020, 17, 1248−1260
1257
The selected analysis methods were complementary and
allowed a better understanding of crystal habit, localization,
and solid-state form, particularly after dissolution. The
macroscopically visible size of the white spots and diffuse
white areas that formed during dissolution testing (Figure 6)
enabled their targeted analysis with SEM and ATR FTIR. With
SEM, white spots were characterized by spherulite-like
structures that formed surface indentations. When these
regions were probed with ATR FTIR, they showed spectra,
corresponding to the ε form of indomethacin. Similarly, diffuse
white areas were characterized by needle morphology with
SEM and ATR FTIR spectra corresponding to α indometha-
cin.
5. CONCLUSIONS
This study shows that while crystallization inhibition during
storage is important, the other factors associated with the
polymers and the coatings themselves can have an equally
important effect on dissolution. The surface stabilization of
amorphous drug during storage, as well as its dissolution
performance in each of the stability test points, were
investigated using a simple tablet-like dosage form spray-
coated as a whole with a thin polymer layer. The selected
characterization techniques (SEM, ATR FTIR, and XRD)
provided complementary data that aided the interpretation of
intrinsic dissolution results.
This study showed that thin polymer coatings are capable of
delaying the onset of crystallization of amorphous drug
compacts stored at an elevated humidity. Thicker, micrometer
range coatings provided two times longer stabilization than the
thinner coatings, which were hundreds of nanometers thick.
The improved storage stabilization of the amorphous drugs
can, at least to some extent, maintain their IDR, but this does
not necessarily guarantee an improvement of the IDRs. Besides
surface stability, other factors (such as the surface, the extent of
precipitation, and the coatings themselves) contribute to the
complexity of dissolution phenomena, and the overall
dissolution performance reflects the interplay of all of these
contributing factors.
This study focused, from a pharmaceutical perspective, on
amorphous surface phenomena, mimicking as much as possible
the standards that would be used by the pharmaceutical
industry and regulators, such as tablet-like compacts, a broadly
used pharmaceutical excipient, and spray coating as well as
pharmacopoeial dissolution tests. This research brings us a step
closer to understanding and utilizing surface crystallization and
its inhibition in amorphous drug formulations.
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